NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Avadel Pharmaceuticals plc (AVDL) Stock Analysis

Avadel Pharmaceuticals plc (AVDL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

AVDL

$21.64

$0.00 (0.00%)

Last trade February 13, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AVDL with… →

AVDL Key Statistics

As of Feb 13, 2026
Trading
Open
$21.64
Previous Close
$21.64
52-Week Range
6.38–23.57
Valuation
Market Cap
$2.13B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
28.89
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.57
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.11%
1-Year Return
+140.71%
Dividend and dates
Avg Volume
1.87M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AVDL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.42%
2025+172.78%

As of February 13, 2026.

AVDL Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricAVDLDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio8.572.303.7x the median
Profit margin−0.11%−3.14%3.0 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Avadel Pharmaceuticals plc (AVDL) carries a market capitalisation of $2.13B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 188 employees.

Over the past 52 weeks the price has ranged from $6.38 to $23.57. The most recent close on file for AVDL is $21.64, dated February 13, 2026. The close was unchanged from the previous session. The latest close sits 239.18% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $248.52M. Profit margin runs at −0.11%. That is 3 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 28.89. Measured against sales, the shares trade at 8.57 times revenue. On price-to-sales that is 3.7 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 47.62%. The trailing one-year price return is +140.71%.

Growth & Income

The record shows no dividend for AVDL.

2026 is still running; the price is +0.42% year to date. The record holds one complete calendar year, 2025, which returned +172.78%.

Peer Comparison

Avadel Pharmaceuticals plc (AVDL) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Avadel Pharmaceuticals plc AVDL $2.13B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Avadel Pharmaceuticals plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of February 13, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Visit website →